Editorial Comment from Dr Yuasa to Effect of active anticancer therapy on serologic response to SARS-CoV-2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma

Int J Urol. 2022 Jul;29(7):740. doi: 10.1111/iju.14920. Epub 2022 May 10.
No abstract available

Publication types

  • Editorial
  • Kommentar

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines / therapeutic use
  • COVID-19* / prevention & control
  • Carcinoma, Renal Cell* / drug therapy
  • Humans
  • Kidney Neoplasms* / drug therapy
  • SARS-CoV-2

Substances

  • COVID-19 Vaccines
  • BNT162 Vaccine